{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:09:24Z","timestamp":1793848164634,"version":"4.6.1"},"reference-count":273,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.pnpbp.2021.110326","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T21:15:50Z","timestamp":1618953350000},"page":"110326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"special_numbering":"C","title":["The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part I: The past and the present"],"prefix":"10.1016","volume":"110","author":[{"given":"Antonio M.","family":"Persico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Ricciardello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lamberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Turriziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cucinotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Brogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Vitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0005","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00004583-198907000-00014","article-title":"Review of fenfluramine in the treatment of the developmental disabilities","volume":"28","author":"Aman","year":"1989","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/BF01046052","article-title":"Fenfluramine and methylphenidate in children with mental retardation and attention deficit hyperactivity disorder: laboratory effects","volume":"23","author":"Aman","year":"1993","journal-title":"J. Autism Dev. Disord."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/104454603321666171","article-title":"Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies","volume":"13","author":"Aman","year":"2003","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0020","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/cap.2005.15.869","article-title":"Acute and long-term safety and tolerability of risperidone in children with autism","volume":"15","author":"Aman","year":"2005","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/cap.2007.0133","article-title":"Posey DJ Cognitive effects of risperidone in children with autism and irritable behavior","volume":"18","author":"Aman","year":"2008","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.pnpbp.2021.110326_bb0030","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/CHI.0b013e3181bfd669","article-title":"Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial","volume":"48","author":"Aman","year":"2009","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110326_bb0035","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/cap.2009.0120","article-title":"Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder","volume":"20","author":"Aman","year":"2010","journal-title":"J. Child Adoles. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0040","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1089\/cap.2015.0005","article-title":"Tolerability,safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial","volume":"25","author":"Aman","year":"2015","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0045","series-title":"Diagnostic and Statistical Manual of Psychiatric Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0050","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/01.jcp.0000227703.72117.bc","article-title":"Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder","volume":"26","author":"Anagnostou","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.pnpbp.2021.110326_bb0055","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/ajp.141.10.1195","article-title":"Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms","volume":"141","author":"Anderson","year":"1984","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0060","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02211843","article-title":"The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children","volume":"19","author":"Anderson","year":"1989","journal-title":"J. Autism Dev. Disord."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0065","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0068","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS Drug Rev."},{"issue":"Suppl. 4","key":"10.1016\/j.pnpbp.2021.110326_bb0070","doi-asserted-by":"crossref","first-page":"S471","DOI":"10.1016\/j.euroneuro.2004.08.006","article-title":"Clinical effectiveness of new generation antipsychotics in adolescent patients","volume":"14","author":"Arango","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.pnpbp.2021.110326_bb0075","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00787-009-0749-5","article-title":"Olanzapine compared to quetiapine in adolescents with a first psychotic episode","volume":"18","author":"Arango","year":"2009","journal-title":"Eur. Child Adolesc. Psychiatry"},{"issue":"9","key":"10.1016\/j.pnpbp.2021.110326_bb0080","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00787-019-01425-2","article-title":"Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis","volume":"29","author":"Arango","year":"2020","journal-title":"Eur. Child Adolesc. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0085","first-page":"363","article-title":"Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children","volume":"31","author":"Armenteros","year":"1995","journal-title":"Psychopharmacol. Bull."},{"issue":"12","key":"10.1016\/j.pnpbp.2021.110326_bb0090","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/00004583-200312000-00011","article-title":"Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials","volume":"42","author":"Arnold","year":"2003","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2021.110326_bb0095","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","article-title":"Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial","volume":"45","author":"Arnold","year":"2006","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2021.110326_bb0100","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jaac.2012.08.028","article-title":"Research Units of Pediatric Psychopharmacology (RUPP) autism network randomized clinical trial of parent training and medication: one-year follow-up","volume":"51","author":"Arnold","year":"2012","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0105","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1089\/cap.2017.0134","article-title":"A 1.5-year follow-up of parent training and atomoxetine for Attention-Deficit\/Hyperactivity Disorder symptoms and noncompliant\/disruptive behavior in autism","volume":"28","author":"Arnold","year":"2018","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0935","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13229-017-0137-9","article-title":"Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia","volume":"8","author":"Autism Spectrum Disorders Working Group of The Psychiatric Genomics Consortium","year":"2017","journal-title":"Mol. Autism"},{"issue":"9","key":"10.1016\/j.pnpbp.2021.110326_bb0110","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.ridd.2013.05.028","article-title":"Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany","volume":"34","author":"Bachmann","year":"2013","journal-title":"Res. Dev. Disabil."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/JCP.0b013e318218f4a1","article-title":"Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors","volume":"31","author":"Beherec","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1010799115457","article-title":"Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Belsito","year":"2001","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0125","doi-asserted-by":"crossref","first-page":"732","DOI":"10.4088\/JCP.08m04821","article-title":"The Child Behavior Checklist Paediatric Bipolar Disorder profile predicts a subsequent diagnosis of bipolar disorder and associated impairments in ADHD youth growing up: a longitudinal analysis","volume":"70","author":"Biederman","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110326_bb0130","first-page":"8","article-title":"The treatment of autism with low dose phenytoin: a case report","volume":"9","author":"Bird","year":"2015","journal-title":"J. Med. Care Rep."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0135","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/phar.1686","article-title":"Management of sleep disorders in children with neurodevelopmental disorders: a review","volume":"36","author":"Blackmer","year":"2016","journal-title":"Pharmacotherapy."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0165-1781(95)02601-R","article-title":"Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study","volume":"58","author":"Bouvard","year":"1995","journal-title":"Psychiatry Res."},{"issue":"Pt 4","key":"10.1016\/j.pnpbp.2021.110326_bb0145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1365-2788.1998.00144.x","article-title":"Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability","volume":"42","author":"Branford","year":"1998","journal-title":"J. Intellect. Disabil. Res."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0150","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archgenpsychiatry.2011.38","article-title":"Epidemiology of autism spectrum disorders in adults in the community in England","volume":"68","author":"Brugha","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2021.110326_bb0155","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.4088\/JCP.14m09258","article-title":"Iron homeostasis during risperidone treatment in children and adolescents","volume":"76","author":"Calarge","year":"2015","journal-title":"J. Clin. Psychiatry."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pediatrneurol.2012.04.002","article-title":"Levetiracetam-induced reversible autistic regression","volume":"47","author":"Camacho","year":"2012","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0165","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF01557348","article-title":"Imipramine in preschool autistic and schizophrenic children","volume":"1","author":"Campbell","year":"1971","journal-title":"J. Autism Child. Schizophr."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0170","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0002-7138(09)61017-7","article-title":"A comparison of haloperidol and behavior therapy and their interaction in autistic children","volume":"17","author":"Campbell","year":"1978","journal-title":"J. Am. Acad. Child Psychiatry."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0175","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF01531306","article-title":"The effects of haloperidol on learning and behavior in autistic children","volume":"12","author":"Campbell","year":"1982","journal-title":"J. Autism Dev. Disord."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0180","first-page":"130","article-title":"Naltrexone in autistic children: a double-blind and placebo-controlled study","volume":"26","author":"Campbell","year":"1990","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0185","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/00004583-199311000-00024","article-title":"Naltrexone in autistic children: behavioral symptoms and attentional learning","volume":"32","author":"Campbell","year":"1993","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0190","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/00004583-199706000-00022","article-title":"Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study","volume":"36","author":"Campbell","year":"1997","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0195","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.braindev.2004.06.006","article-title":"Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders","volume":"27","author":"Canitano","year":"2005","journal-title":"Brain and Development"},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0200","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/WNF.0000000000000096","article-title":"Mood stabilizers in children and adolescents with autism spectrum disorders","volume":"38","author":"Canitano","year":"2015","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0205","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.pnpbp.2005.10.002","article-title":"Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit\/hyperactivity disorders (ADHD)-like symptoms","volume":"30","author":"Carminati","year":"2006","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110326_bb0210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pnpbp.2015.09.002","article-title":"Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder","volume":"65","author":"Carminati","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0215","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.chc.2013.08.002","article-title":"Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems","volume":"23","author":"Carroll","year":"2014","journal-title":"Child Adolesc. Psychiatr. Clin. N. Am."},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2021.110326_bb0220","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijdevneu.2004.08.002","article-title":"Significance of abnormalities in developmental trajectory and asymmetry of cortical serotonin synthesis in autism","volume":"23","author":"Chandana","year":"2005","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0225","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4088\/JCP.v62n0612h","article-title":"Clozapine in the treatment of aggression in an adolescent with autistic disorder","volume":"62","author":"Chen","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0230","first-page":"1","article-title":"pour le Groupe d\u2019\u00c9tude Interdisciplinaire de Bretagne \u00ab\u202fPsychotropes chez l\u2019enfant et l\u2019adolescent\u00bb","volume":"65","author":"Chevreuil","year":"2010","journal-title":"Le traitement pharmacologique de l\u2019insomnie en p\u00e9dopsychiatrie. Therapie"},{"key":"10.1016\/j.pnpbp.2021.110326_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2015.11.033","article-title":"Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with Autism Spectrum Disorder: a randomized trial","volume":"170","author":"Chugani","year":"2016","journal-title":"J. Pediatr."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0240","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0002-7138(09)60969-9","article-title":"Behavioral effects of haloperidol in young autistic children. An objective analysis using a within-subjects reversal design","volume":"19","author":"Cohen","year":"1980","journal-title":"J. Am. Acad. Child Psychiatry."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0245","first-page":"63","article-title":"A study of haloperidol in young autistic children: a within-subjects design using objective rating scales","volume":"16","author":"Cohen","year":"1980","journal-title":"Psychopharmacol. Bull."},{"issue":"11","key":"10.1016\/j.pnpbp.2021.110326_bb0250","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.4088\/JCP.v65n1115","article-title":"A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders","volume":"65","author":"Corson","year":"2004","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0255","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/cap.2008.020","article-title":"Effectiveness of mirtazapine in the treatment of inappropriate sexual behaviors in individuals with autistic disorder","volume":"19","author":"Coskun","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.pnpbp.2021.110326_bb0260","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/cap.2012.0111","volume":"23","author":"Dalsgaard","year":"2013","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110326_bb0265","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1469-8749.1998.tb15414.x","article-title":"Effects of fluoxetine treatment in young children with idiopathic autism","volume":"40","author":"DeLong","year":"1998","journal-title":"Dev. Med. Child Neurol."},{"issue":"10","key":"10.1016\/j.pnpbp.2021.110326_bb0270","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1469-8749.2002.tb00266.x","article-title":"Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement","volume":"44","author":"DeLong","year":"2002","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0275","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fneur.2014.00011","article-title":"Mechanisms of levetiracetam in the control of status epilepticus and epilepsy","volume":"5","author":"Deshpande","year":"2014","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0280","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/phar.2271","article-title":"Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial","volume":"39","author":"DeVane","year":"2019","journal-title":"Pharmacotherapy."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0285","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/1044546041649011","article-title":"Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study","volume":"14","author":"Di Martino","year":"2004","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0290","series-title":"Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders","author":"Dichter","year":"2012"},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0295","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/13554790903559671","article-title":"fMRI tracks reductions in repetitive behaviors in autism: two case studies","volume":"16","author":"Dichter","year":"2010","journal-title":"Neurocase."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0300","article-title":"National and state estimates of adults with autism spectrum disorder [published online ahead of print, 2020 May 10]","author":"Dietz","year":"2020","journal-title":"J. Autism Dev. Disord."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01046402","article-title":"Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function","volume":"22","author":"Dollfus","year":"1992","journal-title":"J. Autism Dev. Disord."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0310","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/cap.1993.3.145","article-title":"Catecholamines in autistic disorder: effects of amisulpride and bromocriptine in a controlled crossover study","volume":"3","author":"Dollfus","year":"1993","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0315","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1089\/cap.2014.0111","article-title":"Retrospective naturalistic study of ziprasidone for irritability in youth with Autism Spectrum Disorder","volume":"25","author":"Dominick","year":"2015","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0320","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s10803-012-1661-2","article-title":"Brief report: retrospective case series of oxcarbazepine for irritability\/agitation symptoms in autism spectrum disorder","volume":"43","author":"Douglas","year":"2013","journal-title":"J. Autism Dev. Disord."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0325","doi-asserted-by":"crossref","first-page":"263","DOI":"10.31887\/DCNS.2012.14.3\/cdoyle","article-title":"Pharmacologic treatments for the behavioral symtoms associated with autism spectrum disorders across the lifespan","volume":"14","author":"Doyle","year":"2012","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-220778","article-title":"Phelan-McDermid syndrome due to SHANK3 mutation in an intellectually disabled adult male: successful treatment with lithium","volume":"2017","author":"Egger","year":"2017","journal-title":"BMJ Case Rep."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0335","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1345\/aph.1G499","article-title":"Efficacy and safety of naltrexone use in pediatric patients with autistic disorder","volume":"40","author":"Elchaar","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0340","first-page":"3033","article-title":"Venlafaxine: a heterocyclic antidepressant","volume":"51","author":"Ellingrod","year":"1994","journal-title":"Am. J. Hosp. Pharm."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0345","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3928\/0090-4481-20070901-09","article-title":"Pharmacologic treatment of autism and related disorders","volume":"36","author":"Erickson","year":"2007","journal-title":"Pediatr. Ann."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0350","first-page":"77","article-title":"A double-blind, placebo controlled study of the efficacy of transdermal clonidine in autism","volume":"53","author":"Fankhauser","year":"1992","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0355","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00004583-199905000-00021","article-title":"Naltrexone and communication skills in young children with autism","volume":"38","author":"Feldman","year":"1999","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110326_bb0360","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/1044546041649129","article-title":"Quetiapine in nine youths with autistic disorder","volume":"14","author":"Findling","year":"2004","journal-title":"J. Child Adoles. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0365","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/JCP.13m08500","article-title":"A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder","volume":"75","author":"Findling","year":"2014","journal-title":"J. Clin. Psychiatry."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0370","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.euroneuro.2014.11.010","article-title":"The pharmacodynamics properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder","volume":"25","author":"Fountoulakis","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0375","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.psychres.2019.04.013","article-title":"Prevalence and predictors of psychotropic medication use in adolescents and adults with autism spectrum disorder in Italy: A cross-sectional study","volume":"276","author":"Fusar-Poli","year":"2019","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0380","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.euroneuro.2014.02.004","article-title":"Blood serotonin levels in autism spectrum disorder: a systematic review and meta-analysis","volume":"24","author":"Gabriele","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0385","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapsychiatry.2015.2923","article-title":"Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis","volume":"73","author":"Galling","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110326_bb0390","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00004714-199108000-00022","article-title":"Trazodone reduced aggressive and self-injurious movements in a mentally handicapped male patient with autism","volume":"11","author":"Gedye","year":"1991","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0395","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00787-007-0656-6","article-title":"Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study","volume":"17","author":"Gencer","year":"2008","journal-title":"Eur. Child Adolesc. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0400","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1017\/S1461145712000880","article-title":"Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"16","author":"Ghaleiha","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2021.110326_bb0405","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.psychres.2015.07.043","article-title":"A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism","volume":"229","author":"Ghaleiha","year":"2015","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0410","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2014.09.017","article-title":"A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism","volume":"52","author":"Ghanizadeh","year":"2015","journal-title":"Pediatr. Neurol."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0415","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10578-013-0390-x","article-title":"A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial","volume":"45","author":"Ghanizadeh","year":"2014","journal-title":"Child Psychiatry Hum. Dev."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0420","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/cap.2008.0137","article-title":"Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit\/hyperactivity disorder symptoms in preschoolers with developmental disorders","volume":"19","author":"Ghuman","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0425","first-page":"340","article-title":"Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour","volume":"26","author":"Gobbi","year":"2001","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0430","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/WNF.0b013e31823349ac","article-title":"Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial","volume":"34","author":"Golubchik","year":"2011","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0435","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/WNF.0b013e31828003c1","article-title":"Reboxetine treatment for autistic spectrum disorder of pediatric patients with depressive and inattentive\/hyperactive symtoms: an open label trial","volume":"36","author":"Golubchik","year":"2013","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0440","first-page":"203","article-title":"Naltrexone plasma levels, clinical response and effect on weight in autistic children","volume":"30","author":"Gonzalez","year":"1994","journal-title":"Psychopharmacol. Bull."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0445","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1176\/ajp.149.3.363","article-title":"Differential response of seven subjects with autistic disorder to clomipramine and desipramine","volume":"149","author":"Gordon","year":"1992","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0450","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.1993.01820180039004","article-title":"A double-blind comparison of clomipramine, desipramine and placebo in the treatment of Autistic Disorder","volume":"50","author":"Gordon","year":"1993","journal-title":"Arch. Gen. Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110326_bb0455","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/DBP.0000000000000334","article-title":"A randomized, double-blind, placebo-controlled trial of low-dose sertraline in young children with Fragile X Syndrome","volume":"37","author":"Greiss Hess","year":"2016","journal-title":"J. Dev. Behav. Pediatr."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0460","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/WNF.0000000000000380","article-title":"A severe adverse effect of atomoxetine: hypertensive crisis","volume":"43","author":"Guldiken","year":"2020","journal-title":"Clin. Neuropharmacol."},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110326_bb0465","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/cap.2019.0025","article-title":"Raynaud\u2019s phenomenon related with atomoxetine treatment in a child with autism and attention-deficit\/hyperactivity disorder","volume":"29","author":"G\u00fclle","year":"2019","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0468","first-page":"548","article-title":"Efficacy and safety of aripiprazole for treatment of irritability in children with autistic disorder: an open-label study","volume":"40","author":"Habibi","year":"2015","journal-title":"Iran J. Med. Sci."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0470","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1005548619694","article-title":"Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder","volume":"30","author":"Handen","year":"2000","journal-title":"J. Autism Dev. Disord."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0475","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/DBP.0b013e3181739b9d","article-title":"Guanfacine in children with autism and\/or intellectual disabilities","volume":"29","author":"Handen","year":"2008","journal-title":"J. Dev. Behav. Pediatr."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0480","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10882-012-9316-y","article-title":"Use of a direct observational measure in a trial of risperidone and parent training in children with pervasive developmental disorders","volume":"25","author":"Handen","year":"2013","journal-title":"J. Dev. Phys. Disabil."},{"issue":"11","key":"10.1016\/j.pnpbp.2021.110326_bb0485","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jaac.2015.08.013","article-title":"Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit\/hyperactivity disorder","volume":"54","author":"Handen","year":"2015","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0490","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10803-005-3306-1","article-title":"Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders","volume":"35","author":"Hardan","year":"2005","journal-title":"J. Autism Dev. Disord."},{"issue":"7","key":"10.1016\/j.pnpbp.2021.110326_bb0495","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaac.2012.04.011","article-title":"A randomized double-blind study of atomoxetine versus placebo for attention-deficit\/hyperactivity disorder symptoms in children with autism spectrum disorder","volume":"51","author":"Harfterkamp","year":"2012","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0500","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1089\/cap.2012.0012","article-title":"Long-term treatment with atomoxetine for attention-deficit\/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study","volume":"23","author":"Harfterkamp","year":"2013","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.pnpbp.2021.110326_bb0505","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1089\/cap.2014.0026","article-title":"Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change","volume":"24","author":"Harfterkamp","year":"2014","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0510","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/cap.2014.0142","article-title":"No evidence for predictors of response to atomoxetine treatment of attention-deficit\/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder","volume":"25","author":"Harfterkamp","year":"2015","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0515","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4161\/cam.3.1.7401","article-title":"Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models","volume":"3","author":"He","year":"2009","journal-title":"Cell Adhes. Migr."},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110326_bb0520","first-page":"333","article-title":"Sertraline response in adults with mental retardation and autistic disorder","volume":"57","author":"Hellings","year":"1996","journal-title":"J. Clin. Psychiatry."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0525","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/10445460152595559","article-title":"Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism","volume":"11","author":"Hellings","year":"2001","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0530","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/cap.2005.15.885","article-title":"Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders","volume":"15","author":"Hellings","year":"2005","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0535","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/cap.2005.15.682","article-title":"A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders","volume":"15","author":"Hellings","year":"2005","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0540","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10803-006-0078-1","article-title":"A crossover study of risperidone in children, adolescents and adults with mental retardation","volume":"36","author":"Hellings","year":"2006","journal-title":"J. Autism Dev. Disord."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0545","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/cap.2014.0003","article-title":"Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability","volume":"25","author":"Hellings","year":"2015","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110326_bb0550","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1089\/cap.2014.0145","article-title":"Low dose loxapine: neuromotor side effects and tolerability in autism spectrum disorders","volume":"25","author":"Hellings","year":"2015","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0555","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/14656566.2017.1308483","article-title":"Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline","volume":"18","author":"Hellings","year":"2017","journal-title":"Expert. Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0560","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.410220419","article-title":"Naltrexone decreases self-injurious behavior","volume":"22","author":"Herman","year":"1987","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0565","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000480969","article-title":"Role for opioid peptides in self-injurious behavior: dissociation from autonomic nervous system functioning","volume":"12","author":"Herman","year":"1989","journal-title":"Dev. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0570","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000480957","article-title":"Effects of acute administration of naltrexone on cardiovascular function, body temperature, body weight and serum concentrations of liver enzymes in autistic children","volume":"12","author":"Herman","year":"1989","journal-title":"Dev. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0575","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/cap.1993.3.157","article-title":"Cardiovascular and other physical effects of acute administration of naltrexone in autistic children","volume":"3","author":"Herman","year":"1993","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.pnpbp.2021.110326_bb0580","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1007\/s10803-019-04120-y","article-title":"The SOFIA study: negative multi-center study of low dose fluoxetine on repetitive behaviors in children and adolescents with Autistic Disorder","volume":"50","author":"Herscu","year":"2020","journal-title":"J. Autism Dev. Disord."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0585","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s10803-013-1952-2","article-title":"Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis","volume":"44","author":"Hirota","year":"2014","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0590","series-title":"Clinical Manual for the Treatment of Autism","first-page":"99","author":"Hollander","year":"2007"},{"key":"10.1016\/j.pnpbp.2021.110326_bb0595","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/088307380001500214","article-title":"Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report","volume":"15","author":"Hollander","year":"2000","journal-title":"J. Child Neurol."},{"issue":"7","key":"10.1016\/j.pnpbp.2021.110326_bb0600","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4088\/JCP.v62n07a05","article-title":"An open trial of divalproex sodium in autism spectrum disorders","volume":"62","author":"Hollander","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0605","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.npp.1300627","article-title":"A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviours in childhood and adolescent autism","volume":"30","author":"Hollander","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0610","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A double-blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder","volume":"16","author":"Hollander","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0615","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1017\/S1461145705005791","article-title":"Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder","volume":"9","author":"Hollander","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0620","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/npp.2009.202","article-title":"Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders","volume":"35","author":"Hollander","year":"2010","journal-title":"Neuropsychopharmacology."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0625","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/cap.2017.0085","article-title":"Atomoxetine, parent training, and their effects on sleep in youth with autism spectrum disorder and attention-deficit\/hyperactivity disorder","volume":"28","author":"Hollway","year":"2018","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0630","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00213-013-3263-x","article-title":"Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study","volume":"231","author":"Hsia","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2021.110326_bb0633","first-page":"CD008372","article-title":"Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents","volume":"3","author":"Hurwitz","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0635","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s10578-016-0704-x","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with Autism Spectrum Disorder in Japan: a randomized, double-blind, placebo-controlled study","volume":"48","author":"Ichikawa","year":"2017","journal-title":"Child Psychiatry Hum. Dev."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0640","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/pcn.12607","article-title":"An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan","volume":"72","author":"Ichikawa","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0645","first-page":"104317","article-title":"Sertraline may improve language developmental trajectory in young children with fragile x syndrome: a retrospective chart review","volume":"2012","author":"Indah Winarni","year":"2012","journal-title":"Autism Res Treat."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0650","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/WNF.0b013e3182a31ec0","article-title":"Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study","volume":"36","author":"Ishitobi","year":"2013","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0655","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10803-008-0636-9","article-title":"Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity","volume":"39","author":"Jahromi","year":"2009","journal-title":"J. Autism Dev. Disord."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0660","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s10803-015-2675-3","article-title":"Loxapine for reversal of antipsychotic-induced metabolic disturbances: a chart review","volume":"46","author":"Jain","year":"2016","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0665","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199210000-00005","article-title":"Clonidine treatment of hyperactive and impulsive children with autistic disorder","volume":"12","author":"Jaselskis","year":"1992","journal-title":"Clin Psychopharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0670","doi-asserted-by":"crossref","first-page":"157","DOI":"10.17245\/jdapm.2017.17.2.157","article-title":"Managing the behavior of a patient with autism by sedation via submucosal route during dental treatment","volume":"17","author":"Jo","year":"2017","journal-title":"J. Dent. Anesth. Pain Med."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0675","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/acps.12644","article-title":"Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review","volume":"135","author":"Jobski","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0680","first-page":"1","article-title":"A prospective open-label trial of long-acting liquid methylphenidate for the treatment of attention deficit\/hyperactivity disorder in intellectually capable adults with autism spectrum disorder","volume":"19","author":"Joshi","year":"2019","journal-title":"World J. Biol. Psychiatry."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0685","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1024466819989","article-title":"Brief report: clonazepam behavioral side effects with an individual with mental retardation","volume":"33","author":"Kalachnik","year":"2003","journal-title":"J. Autism Dev. Disord."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0690","first-page":"455","article-title":"Pharmacologic management of agitation and aggression in a pediatric Emergency Department - a retrospective cohort study","volume":"23","author":"Kendrick","year":"2018","journal-title":"J. Pediatr. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110326_bb0695","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10803-012-1723-5","article-title":"Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study","volume":"43","author":"Kent","year":"2013","journal-title":"J. Autism Dev. Disord."},{"issue":"10","key":"10.1016\/j.pnpbp.2021.110326_bb0700","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1089\/cap.2012.0058","article-title":"An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder","volume":"23","author":"Kent","year":"2013","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0705","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00004714-198712000-00005","article-title":"Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology","volume":"7","author":"Kerbeshian","year":"1987","journal-title":"J. Clin. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110326_bb0710","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s10803-017-3125-1","article-title":"Dose-response effects of long-acting liquid methylphenidate in children with Attention Deficit\/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): a pilot study","volume":"47","author":"Kim","year":"2017","journal-title":"J. Autism Dev. Disord."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0715","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/00004583-200106000-00010","article-title":"Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder","volume":"40","author":"King","year":"2001","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0720","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archgenpsychiatry.2009.30","article-title":"Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism","volume":"66","author":"King","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2021.110326_bb0725","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jamapediatrics.2013.2698","article-title":"Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial","volume":"167","author":"King","year":"2013","journal-title":"JAMA Pediatr."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0730","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00004583-199502000-00018","article-title":"Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study","volume":"34","author":"Kolmen","year":"1995","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2021.110326_bb0735","first-page":"1570","article-title":"Naltrexone in young autistic children: replication study and learning measures","volume":"36","author":"Kolmen","year":"1997","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0740","first-page":"298","article-title":"Clinical study of the response to nortriptyline on autistic children","volume":"2","author":"Kurtis","year":"1966","journal-title":"Int. J. Neuropsychiatry."},{"issue":"11","key":"10.1016\/j.pnpbp.2021.110326_bb0745","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1016\/j.celrep.2018.08.022","article-title":"Comparative analyses of copy-number variation in autism spectrum disorder and schizophrenia reveal etiological overlap and biological insights","volume":"24","author":"Kushima","year":"2018","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0750","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40272-016-0183-3","article-title":"Head-to-head comparison of aripiprazole and risperidone in the treatment of ADHD symptoms in children with Autistic Spectrum Disorder and ADHD: a pilot, open-label, randomized controlled study","volume":"18","author":"Lamberti","year":"2016","journal-title":"Paediatr Drugs."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0755","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01058158","article-title":"Brief report: a double-blind study of naltrexone in infantile autism","volume":"22","author":"Leboyer","year":"1992","journal-title":"J. Autism Dev. Disord."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0760","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s10803-017-3345-4","article-title":"Parent stress in a randomized clinical trial of atomoxetine and parent training for children with autism spectrum disorder","volume":"48","author":"Lecavalier","year":"2018","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0765","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eurpsy.2015.11.004","article-title":"Initial severity and efficacy of risperidone in autism: results from the RUPP trial","volume":"32","author":"Levine","year":"2016","journal-title":"Eur Psychiatry."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0770","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/13668250601006924","article-title":"Dietary status and impact of risperidone on nutritional balance in children with autism: a pilot study","volume":"31","author":"Lindsay","year":"2006","journal-title":"J. Intellect. Develop. Disabil."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0775","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1192\/bjp.156.3.430","article-title":"Tourette-like disorder in Asperger\u2019s syndrome","volume":"156","author":"Littlejohns","year":"1990","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0780","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10803-015-2628-x","article-title":"Lurasidone for the treatment of irritability associated with autistic disorder","volume":"46","author":"Loebel","year":"2016","journal-title":"J. Autism Dev. Disord."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0785","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/cap.2006.16.575","article-title":"Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy","volume":"16","author":"Luby","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0790","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6904a1","article-title":"Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2016","volume":"69","author":"Maenner","year":"2020","journal-title":"MMWR Surveill. Summ."},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110326_bb0795","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00004583-200108000-00009","article-title":"Olanzapine versus haloperidol in children with autistic disorder: an open pilot study","volume":"40","author":"Malone","year":"2001","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0800","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/cap.2006.0126","article-title":"Ziprasidone in adolescents with autism: an open-label pilot study","volume":"17","author":"Malone","year":"2007","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.pnpbp.2021.110326_bb0805","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1542\/peds.2015-2851H","article-title":"Sleep difficulties and medications in children with autism spectrum disorders: a registry study","volume":"137","author":"Malow","year":"2016","journal-title":"Pediatrics."},{"issue":"9","key":"10.1016\/j.pnpbp.2021.110326_bb0810","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1592\/phco.24.13.1177.38089","article-title":"Paradoxical reactions to benzodiazepines: literature review and treatment options","volume":"24","author":"Mancuso","year":"2004","journal-title":"Pharmacotherapy."},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110326_bb0815","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1089\/cap.2012.0075","article-title":"Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change","volume":"23","author":"Mankoski","year":"2013","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.pnpbp.2021.110326_bb0820","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"9","key":"10.1016\/j.pnpbp.2021.110326_bb0825","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4088\/JCP.09m05933","article-title":"Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study","volume":"72","author":"Marcus","year":"2011","journal-title":"J. Clin. Psychiatry."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0830","first-page":"355","article-title":"Paradoxical reactions elicited by diazepam in children with classic autism","volume":"2","author":"Marrosu","year":"1987","journal-title":"Funct. Neurol."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0835","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/cap.1999.9.99","article-title":"Open-label quetiapine in the treatment of children and adolescents with autistic disorder","volume":"9","author":"Martin","year":"1999","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0840","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.161.6.1125","article-title":"Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data","volume":"161","author":"Martin","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0845","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00023210-200923060-00005","article-title":"Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study","volume":"23","author":"Masi","year":"2009","journal-title":"CNS Drugs."},{"issue":"10","key":"10.1016\/j.pnpbp.2021.110326_bb0850","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.braindev.2006.05.004","article-title":"Topiramate in children with autistic spectrum disorders","volume":"28","author":"Mazzone","year":"2006","journal-title":"Brain and Development"},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0855","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Research units on pediatric psychopharmacology autism network. Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0860","first-page":"295","article-title":"Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders","volume":"14","author":"McCracken","year":"2014","journal-title":"Pharm. J."},{"issue":"11","key":"10.1016\/j.pnpbp.2021.110326_bb0865","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/archpsyc.1996.01830110037005","article-title":"A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder","volume":"53","author":"McDougle","year":"1996","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0870","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00004714-199802000-00010","article-title":"Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation","volume":"18","author":"McDougle","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0875","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1005551523657","article-title":"Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors","volume":"30","author":"McDougle","year":"2000","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0880","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00004583-200208000-00010","article-title":"Case series: use of ziprasidone for maladaptive symptoms in youths with autism","volume":"41","author":"McDougle","year":"2002","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110326_bb0885","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology","volume":"162","author":"McDougle","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0890","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/mp.2009.80","article-title":"The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation","volume":"15","author":"McEwen","year":"2010","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb0900","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004714-198906000-00009","article-title":"Differentiation of stereotypies from neuroleptic-related dyskinesias in autistic children","volume":"9","author":"Meiselas","year":"1989","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0905","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/sj.mp.4000880","article-title":"The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine","volume":"6","author":"Melone","year":"2001","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2021.110326_bb0910","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.braindev.2007.12.007","article-title":"Use of clonidine in children with autism spectrum disorders","volume":"30","author":"Ming","year":"2008","journal-title":"Brain and Development"},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0915","first-page":"28","article-title":"Revisiting lithium: utility for behavioral stabilization in adolescents and adults with Autism Spectrum Disorder","volume":"49","author":"Mintz","year":"2019","journal-title":"Psychopharmacol. Bull."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0920","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00787-007-0620-5","article-title":"Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial","volume":"17","author":"Miral","year":"2008","journal-title":"Eur. Child Adolesc. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0925","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182a9339d","article-title":"Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study","volume":"36","author":"Mohammadi","year":"2013","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0940","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/08830738060210060801","article-title":"Risperidone in children with autism: randomized, placebo-controlled, double-blind study","volume":"21","author":"Nagaraj","year":"2006","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0945","article-title":"Prevalence of Autism Spectrum Disorder in a large Italian catchment area: a school-based population study within the ASDEU project","volume":"29","author":"Narzisi","year":"2018","journal-title":"Epidemiol. Psychiatr Sci."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0950","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hup.491","article-title":"Tianeptine: A novel strategy of psychopharmacological treatment of children with autistic disorder","volume":"18","author":"Niederhofer","year":"2003","journal-title":"Human Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0955","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/WNF.0000000000000063","article-title":"N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety","volume":"38","author":"Nikoo","year":"2015","journal-title":"Clin. Neuropharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb0960","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb0965","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/01.chi.0000153229.80215.a0","article-title":"An open-label trial of escitalopram in pervasive developmental disorders","volume":"44","author":"Owley","year":"2005","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/aur.109","article-title":"A pharmacogenetic study of escitalopram in autism spectrum disorders","volume":"3","author":"Owley","year":"2010","journal-title":"Autism Res."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb0975","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","article-title":"Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Pandina","year":"2007","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0980","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0166-2236(79)90071-7","article-title":"A neurochemical theory of autism","volume":"2","author":"Panksepp","year":"1979","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.pnpbp.2021.110326_bb0985","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0149-7634(80)90036-6","article-title":"Endogeneous opioids and social behavior","volume":"4","author":"Panksepp","year":"1980","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb0990","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/DBP.0b013e31823969de","article-title":"Autism spectrum disorders and health care expenditures: the effects of co-occuring conditions","volume":"33","author":"Peacock","year":"2012","journal-title":"J. Dev. Behav. Pediatr."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0995","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/cap.2012.0096","article-title":"Effects of extended release methylphenidate treatment on ratings of attention-deficit\/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms","volume":"23","author":"Pearson","year":"2013","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.pnpbp.2021.110326_bb1000","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1089\/cap.2020.0004","article-title":"Effects of extended-release methylphenidate treatment on cognitive task performance in children with autism spectrum disorder and attention-deficit\/hyperactivity disorder","volume":"30","author":"Pearson","year":"2020","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"403","key":"10.1016\/j.pnpbp.2021.110326_bb1005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-0447.2000.tb10944.x","article-title":"Safety and tolerability considerations: tricyclic antidepressants versus serotonin reuptake inhibitors. Review","volume":"101","author":"Peretti","year":"2000","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb1010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004583-198901000-00016","article-title":"Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration","volume":"28","author":"Perry","year":"1989","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb1015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00004583-198901000-00017","article-title":"Tourette-like symptoms associated with neuroleptic therapy in an autistic child","volume":"28","author":"Perry","year":"1989","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110326_bb1020","doi-asserted-by":"crossref","unstructured":"Persico AM, Arango C, Buitelaar JK, Correll CU, Glennon JC, Hoekstra PJ, Moreno C, Vitiello B, Vorstman J, Zuddas A; European Child and Adolescent Clinical Psychopharmacology Network. Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. Eur. Neuropsychopharmacol. 2015 Oct;25(10):1513-31.","DOI":"10.1016\/j.euroneuro.2015.06.009"},{"key":"10.1016\/j.pnpbp.2021.110326_bb1025","doi-asserted-by":"crossref","unstructured":"Persico AM, Cucinotta F, Ricciardello A, Turriziani L. Chapter 3. Autisms. In: \u201cComprehensive Developmental Neuroscience. Neurodevelopmental Disorders\u201d, 1st Edition (Rubenstein JLR and Rakic P, Senior Eds; Chen B and Kwan K, Eds; Wynshaw-Boris A, Section Ed). New York (NY): Academic Press\/Elsevier Inc., pag. 35-77, 2020 (ISBN: 978-0-12-814409-1).","DOI":"10.1016\/B978-0-12-814409-1.00003-3"},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb1030","first-page":"198","article-title":"Comparison of the effectiveness of oral diazepam and midazolam for the sedation of autistic patients during dental treatment","volume":"27","author":"Pisalchaiyong","year":"2005","journal-title":"Pediatr. Dent."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb1035","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00213-013-3068-y","article-title":"Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders","volume":"231","author":"Politte","year":"2014","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110326_bb1040","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/s41386-018-0039-3","article-title":"A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures","volume":"43","author":"Politte","year":"2018","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pnpbp.2021.110326_bb1045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/10445460152595586","article-title":"A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders","volume":"11","author":"Posey","year":"2001","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb1050","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/1044546041649084","article-title":"Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases","volume":"14","author":"Posey","year":"2004","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb0288","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1089\/cap.2006.16.599","article-title":"Open-label atomoxetine for attention-deficit\/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders","volume":"16","author":"Posey","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb1055","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.biopsych.2006.09.028","article-title":"Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures","volume":"61","author":"Posey","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110326_bb1060","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3389\/fpsyt.2019.00810","article-title":"A randomized controlled trial of sertraline in young children With Autism Spectrum Disorder","volume":"10","author":"Potter","year":"2019","journal-title":"Front. Psychiatry."},{"issue":"9","key":"10.1016\/j.pnpbp.2021.110326_bb1065","article-title":"Electroencephalographic abnormalities in autism spectrum disorder: characteristics and therapeutic implications","volume":"56","author":"Precenzano","year":"2020","journal-title":"Medicina (Kaunas)."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb1070","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF02179289","article-title":"Use of methylphenidate in the treatment of children with autistic disorder","volume":"25","author":"Quintana","year":"1995","journal-title":"J. Autism Dev. Disord."},{"issue":"16","key":"10.1016\/j.pnpbp.2021.110326_bb1075","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.2019.14685","article-title":"Effect of fluoxetine on obsessive-compulsive behaviors in children and adolescents with autism spectrum disorders: a randomized clinical trial","volume":"322","author":"Reddihough","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.pnpbp.2021.110326_bb1080","doi-asserted-by":"crossref","unstructured":"Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J. Clin. Psychopharmacol. 2001;21(4):440\u20134.","DOI":"10.1097\/00004714-200108000-00012"},{"key":"10.1016\/j.pnpbp.2021.110326_bb1085","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months","volume":"162","author":"RUPPAN - Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2021.110326_bb1090","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.pnpbp.2010.07.005","article-title":"Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder","volume":"34","author":"Rezaei","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb1095","article-title":"Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studies","volume":"13","author":"Robb","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"issue":"7","key":"10.1016\/j.pnpbp.2021.110326_bb1100","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s10803-019-04014-z","article-title":"The economic costs of autism spectrum disorder: a literature review","volume":"49","author":"Rogge","year":"2019","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pnpbp.2021.110326_bb1105","series-title":"Handbook of Psychiatric Drug Therapy","year":"2005"},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb1110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00004703-200208000-00006","article-title":"Levetiracetam in autistic children: an open-label study","volume":"23","author":"Rugino","year":"2002","journal-title":"J. Dev. Behav. Pediatr."},{"issue":"10","key":"10.1016\/j.pnpbp.2021.110326_bb1115","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/npp.2017.60","article-title":"The behavioral effects of the antidepressant tianeptine require the mu-opioid receptor","volume":"42","author":"Samuels","year":"2017","journal-title":"Neuropsychopharmacology."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb1120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1744-6171.2007.00080.x","article-title":"Treatment of hyperactivity in children with pervasive developmental disorders","volume":"20","author":"Scahill","year":"2007","journal-title":"J. Child Adolesc. Psychiatr. Nurs."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb1125","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/cap.2006.16.589","article-title":"A prospective open trial of guanfacine in children with pervasive developmental disorders","volume":"16","author":"Scahill","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb1130","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaac.2011.11.010","article-title":"Research Units on Pediatric Psychopharmacology Autism Network. Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems","volume":"51","author":"Scahill","year":"2012","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb1135","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10803-012-1689-3","article-title":"Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials","volume":"43","author":"Scahill","year":"2013","journal-title":"J. Autism Dev. Disord."},{"issue":"12","key":"10.1016\/j.pnpbp.2021.110326_bb1140","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1176\/appi.ajp.2015.15010055","article-title":"RUPPAN. Extended- Release Guanfacine for hyperactivity in the children with autism spectrum disorders","volume":"172","author":"Scahill","year":"2015","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb1145","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaac.2016.02.016","article-title":"Weight gain and metabolic consequences of risperidone in young children with Autism Spectrum Disorder","volume":"55","author":"Scahill","year":"2016","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb1150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/cap.2016.0107","article-title":"Using a patient-centered outcome measure to test methylphenidate versus placebo in children with Autism Spectrum Disorder","volume":"27","author":"Scahill","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb1155","first-page":"351","article-title":"Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone","volume":"32","author":"Scifo","year":"1996","journal-title":"Ann. Ist. Super. Sanita"},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb1160","first-page":"154","article-title":"Haloperidol -- its use in children","volume":"42","author":"Serrano","year":"1981","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.pnpbp.2021.110326_bb1165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12888-015-0490-1","article-title":"Lithium as a rescue therapy for regression and catatonia in two SHANK3 patients with autism spectrum disorder: case reports","volume":"15","author":"Serret","year":"2015","journal-title":"BMC Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110326_bb1170","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb1175","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/0269881116636107","article-title":"BAP position statement: Off-label prescribing of psychotropic medication to children and adolescents","volume":"30","author":"Sharma","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb1180","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics."},{"issue":"7","key":"10.1016\/j.pnpbp.2021.110326_bb1185","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1089\/cap.2014.0019","article-title":"Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder","volume":"24","author":"Siegel","year":"2014","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb1190","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1469-7610.2012.02569.x","article-title":"Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability","volume":"54","author":"Simonoff","year":"2013","journal-title":"J. Child Psychol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb1195","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0193-953X(18)30331-9","article-title":"Use of medication in pervasive developmental disorders","volume":"14","author":"Sloman","year":"1991","journal-title":"Psychiatr. Clin. North Am."},{"issue":"10","key":"10.1016\/j.pnpbp.2021.110326_bb1200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaac.2016.06.015","article-title":"Atomoxetine and parent training for children with autism and attention-deficit\/hyperactivity disorder: a 24-Week Extension Study","volume":"55","author":"Smith","year":"2016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110326_bb1205","article-title":"Stahl\u2019s essential psychopharmacology: neuroscientific basis and practical applications","author":"Stahl","year":"2013","journal-title":"Cambridge University Press."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb1210","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/00004583-198726060-00021","article-title":"Lithium responsive manic-like symptoms in two individuals with autism and mental retardation","volume":"26","author":"Steingard","year":"1987","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb1215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/cap.1997.7.9","article-title":"Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder","volume":"7","author":"Steingard","year":"1997","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110326_bb1220","first-page":"11","article-title":"Methylphenidate for children and adolescents with autism spectrum disorder","volume":"21","author":"Sturman","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb1225","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10803-005-3305-2","article-title":"Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism","volume":"35","author":"Sugie","year":"2005","journal-title":"J. Autism Dev. Disord."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb1230","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/jpc.14848","article-title":"Severe movement disorder and psychosis from haloperidol withdrawal in a 7-year-old girl with autism","volume":"57","author":"Syamkumar","year":"2021","journal-title":"J. Paediatr. Child Health"},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb1235","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mrdd.20031","article-title":"Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis","volume":"10","author":"Symons","year":"2004","journal-title":"Ment. Retard. Dev. Disabil. Res. Rev."},{"issue":"5","key":"10.1016\/j.pnpbp.2021.110326_bb1240","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2006.16.611","article-title":"Atomoxetine for attention-deficit\/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study","volume":"16","author":"Troost","year":"2006","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.pnpbp.2021.110326_bb1245","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1089\/cap.2016.0187","article-title":"Adverse events of atomoxetine in a double-blind placebo-controlled study in children with autism","volume":"27","author":"Tumuluru","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"13","key":"10.1016\/j.pnpbp.2021.110326_bb1250","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1177\/0883073815579705","article-title":"Parental stress in families of children with autism and other developmental disabilities","volume":"30","author":"Valicenti-McDermott","year":"2015","journal-title":"J. Child Neurol."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb1255","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/JCP.0b013e31829c764f","article-title":"A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit\/hyperactivity disorder symptoms","volume":"33","author":"van der Meer","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110326_bb1260","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s10567-011-0097-0","article-title":"Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis","volume":"14","author":"van Steensel","year":"2011","journal-title":"Clin. Child. Fam. Psychol. Rev."},{"issue":"10","key":"10.1016\/j.pnpbp.2021.110326_bb1265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaac.2016.07.768","article-title":"Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder","volume":"55","author":"Varigonda","year":"2016","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb1270","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.clinthera.2012.02.023","article-title":"Effect of aripiprazole 2 to 15 mg\/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials","volume":"34","author":"Varni","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.pnpbp.2021.110326_bb1275","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.neubiorev.2016.03.019","article-title":"Autism spectrum disorder and attention-deficit\/hyperactivity disorder in early childhood: a review of unique and shared characteristics and developmental antecedents","volume":"65","author":"Visser","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"10","key":"10.1016\/j.pnpbp.2021.110326_bb1280","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1089\/cap.2016.0090","article-title":"No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder","volume":"26","author":"Vo","year":"2016","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb1285","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/acps.12980","article-title":"Treatment of catatonia in autism spectrum disorders","volume":"139","author":"Wachtel","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2021.110326_bb1290","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2147\/NDT.S143966","article-title":"Levetiracetam is associated with decrease in subclinical epileptiform discharges and improved cognitive functions in pediatric patients with autism spectrum disorder","volume":"13","author":"Wang","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb1295","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.yic.0000224787.13782.0f","article-title":"Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study","volume":"21","author":"Wasserman","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2021.110326_bb1300","series-title":"Therapies for children with autism spectrum disorder: behavioral interventions update [Internet].Editors Source Rockville (MD): Agency for Healthcare Research and Quality (US)","author":"Weitlauf","year":"2014"},{"issue":"3","key":"10.1016\/j.pnpbp.2021.110326_bb1305","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0165-1781(95)02749-M","article-title":"Placebo-controlled acute dosage naltrexone study in young autistic children","volume":"58","author":"Willemsen-Swinkels","year":"1995","journal-title":"Psychiatry Res."},{"issue":"12","key":"10.1016\/j.pnpbp.2021.110326_bb1310","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0006-3223(95)00297-9","article-title":"The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study","volume":"39","author":"Willemsen-Swinkels","year":"1996","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb1315","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1023000929040","article-title":"Brief report: six months continuation treatment in naltrexone-responsive children with autism: an open-label case-control design","volume":"29","author":"Willemsen-Swinkels","year":"1999","journal-title":"J. Autism Dev. Disord."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb1325","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1005674016014","article-title":"Brief report: case reports on naltrexone use in children with autism: controlled observations regarding benefits and practical issues of medication management","volume":"31","author":"Williams","year":"2001","journal-title":"J. Autism Dev. Disord."},{"issue":"4","key":"10.1016\/j.pnpbp.2021.110326_bb1330","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/01.chi.0000196423.80717.32","article-title":"Risperidone and adaptive behavior in children with autism","volume":"45","author":"Williams","year":"2006","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110326_bb1335","article-title":"Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)","volume":"8","author":"Williams","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.pnpbp.2021.110326_bb1340","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/cap.2013.0099","article-title":"Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole","volume":"24","author":"Wink","year":"2014","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2021.110326_bb1345","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1023\/A:1005651829910","article-title":"Pilot study of the behavioral effects of flumazenil in two children with autism","volume":"30","author":"Wray","year":"2000","journal-title":"J. Autism Dev. Disord."},{"issue":"9","key":"10.1016\/j.pnpbp.2021.110326_bb1350","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1089\/cap.2015.0020","article-title":"A Retrospective Investigation of Clozapine Treatment in Autistic and Nonautistic Children and Adolescents in an Inpatient Clinic in Turkey","volume":"26","author":"Yalcin","year":"2016","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2021.110326_bb1355","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12888-020-2477-9","article-title":"Pharmacotherapy of restricted\/repetitive behavior in autism spectrum disorder:a systematic review and meta-analysis","volume":"20","author":"Yu","year":"2020","journal-title":"BMC Psychiatry."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584621000853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584621000853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:00:19Z","timestamp":1759521619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584621000853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":273,"alternative-id":["S0278584621000853"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2021.110326","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part I: The past and the present","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2021.110326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110326"}}